BMY NYSE Week ended 18 Sep 2026

Weekly Investor Report

Bristol-Myers Squibb Company · Healthcare · Drug Manufacturers - General

Open interactive chart View report data
Latest close 63.06 USD
-0.9% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 5.1% above the Trend Line and sits at 79.4% of its 52-week range. The latest completed week returned -0.9%, after a -5.9% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is bearish with 47/100 conviction, while the latest news-sentiment score is 58/100. Near-term considerations: earnings are due in 39d.

Setup score 57 out of 100
Latest Close 63.06 USD 18 Sep 2026
1W Return -0.9% latest completed week
4W Return -5.9% short-term follow-through
12W Return 10.8% quarterly tape
Trend Breadth 73.1% 38 of 52 weeks active
Volume Ratio 1.4x vs 13-week average
What is working
  • The trend backdrop is active with a 10-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • 4 reversal markers appear in the recent smart-money tape.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -0.9% Latest completed week; four-week move -5.9%. Indicator stack 75/56 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Bearish 47/100 conviction; expected move 1.8%. News sentiment 58/100 174 relevant articles in the latest sentiment read. Event risk 39d Next report is scheduled for 29 Oct 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 5.1% above the Trend Line and sits at 79.4% of its 52-week range. The latest completed week returned -0.9%, after a -5.9% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.4x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug 14 Aug 21 Aug 28 Aug 4 Sep 11 Sep 18 Sep
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.9212-week average 0.67

12-week confirmation

Trend active10/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure8/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership11/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.92Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers44 reversal markers

No recent accumulation markers. 4 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -5.9% over four weeks, 10.8% over 12 weeks, and 45.2% over one year. The current trend has remained active for 10 consecutive weeks.

Performance by holding period

1W-0.9%
4W-5.9%
12W10.8%
26W10.9%
52W45.2%
Active trend streak10 weeks
Active weeks in one year38
Trend breadth73.1%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.56Latest activity-pressure read.
Pressure change-47.7%Four-week change in activity pressure.
Leadership4.44Latest relative-leadership reading.
RS change-64.1%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 11 Sep 2026 Financial statements through 30 Jun 2026 Field coverage 97% Model confidence 97%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength96/100Blend of value, momentum, and quality. Underlying universe rank 5; rank 1 is best.
Value79/100Relative valuation strength. Underlying universe rank 22; rank 1 is best.
Quality99/100Profitability and accounting quality. Underlying universe rank 2; rank 1 is best.
Momentum86/100Medium-term price momentum. Underlying universe rank 15; rank 1 is best.
Growth74/100Revenue and earnings growth. Underlying universe rank 27; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework87/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
14.0x
Price divided by trailing earnings.
Price / sales
2.6x
Market value relative to trailing revenue.
EV / EBITDA
9.7x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
7.0%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
70.2%
Gross profit retained from each unit of revenue.
Operating margin
28.3%
Operating profit retained from revenue.
Free-cash-flow margin
23.3%
Free cash flow generated from revenue.
Return on invested capital
19.1%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
3.1%
Latest one-year revenue growth.
EPS growth
83.8%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-21.5%
Latest one-year free-cash-flow growth.
Piotroski F-score
8/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
3.9%
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
3.9%
Dividend yield plus net buyback yield.
Net debt / EBITDA
2.0x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBearish

BMY shows bearish options pressure with a 47/100 conviction score, put-call volume ratio of 2.86, expected move of 1.8%, and Sharemaestro trend signal active.

Conviction47/100
Expected move1.8%
Put/call volume2.86
Pressure-48
Speculation41
Volatility28
Trend agreement60
Open options detail
Insider activity9 / 11

9 acquisitions and 11 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment58/100

Weighted news tone is positive across 174 relevant articles.

64 positive · 99 neutral · 11 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings39dNext report is scheduled for 29 Oct 2026; event risk rises as the date approaches.
Options expected move1.8%Nearest-chain priced movement where available.
52-week drawdown-8.1%Distance below the 52-week high.
13-week volatility3.3%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+6.5%Week of 26 Jun.
Worst week-5.5%Week of 19 Jun.
Latest week-0.9%Week of 18 Sep.

Shape of recent returns

Strong gains5
Modest gains8
Flat weeks0
Modest losses11
Sharp losses2
Recent vol3.3%13-week weekly-return volatility.
Base vol3.4%52-week weekly-return volatility.
Up/down split26/26Count of positive and negative weeks in the 52-week window.
Average skew3.4% / -1.9%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape59/100

Trend, activity pressure, participation, and risk combine to a 59/100 tape read.

 Indicator analysis69/100

Latest 12-week confirmation: trend 10/12, activity pressure 8/12, relative leadership 11/12.

Activity pressure 0.92; 4 reversal markers Factors90/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 65 SVQF87/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 134.5 of 1017 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options43/100

BMY shows bearish options pressure with a 47/100 conviction score, put-call volume ratio of 2.86, expected move of 1.8%, and Sharemaestro trend signal active.

Bearish · Put-side pressure · Expected move 1.8% Sentiment58/100

Weighted news tone is positive across 174 relevant articles.

Bristol-Myers Squibb stock steadies as ORM-6151 halt offsets strong Q2 results Insiders9 / 11

9 acquisitions and 11 disposals in the latest 180-day insider tape.

 Earnings39d

Next report is scheduled for 29 Oct 2026; event risk rises as the date approaches.

 Research flow2 items

2 recent research articles and 0 Market Watch posts are available.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
18 Sep 202663.06 USD-0.9%59.99 USD49.84 USD0.564.4475.4MOn
11 Sep 202663.64 USD-4.8%59.89 USD49.77 USD0.645.7429.7MOn
4 Sep 202666.82 USD0.4%59.77 USD49.69 USD0.7610.5738.5MOn
28 Aug 202666.58 USD-0.6%59.59 USD49.61 USD0.9110.7332.5MOn
21 Aug 202667.01 USD5.0%59.18 USD49.53 USD1.0612.4046.9MOn
14 Aug 202663.83 USD-1.4%58.75 USD49.45 USD0.916.0044.7MOn
7 Aug 202664.72 USD-0.9%58.45 USD49.39 USD0.837.8887.1MOn
31 Jul 202665.31 USD5.2%58.13 USD49.32 USD0.3113.0668.7MOn
24 Jul 202662.09 USD2.2%57.72 USD49.24 USD-0.139.1544.4MOn
17 Jul 202660.74 USD5.5%57.43 USD49.19 USD-0.286.4161.1MOn
10 Jul 202657.58 USD-0.9%57.17 USD49.16 USD-0.71-0.4846.2MOff
3 Jul 202658.13 USD2.2%56.96 USD49.14 USD-0.831.9244.3MOff
26 Jun 202656.90 USD6.5%56.73 USD49.12 USD-0.932.0588.1MOff
19 Jun 202653.42 USD-5.5%56.43 USD49.11 USD-1.12-6.3466.2MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context